Application value of mixed reality in hepatectomy for hepatocellular carcinoma

Table 1 The clinical characteristic of 95 patients

Characteristic	Patient (n = 95)		P value
	Group A (n = 37)	Group B (n = 58)
Age (yr), n (%)	57.62 ± 9.16	60.22 ± 9.19	0.819
Sex (female/male), n (%)	13/24	15/43	0.334
BMI	23.91 ± 3.66	23.82 ± 3.42	0.471
History of abdominal surgery (yes/no), n (%)	9/28	11/47	0.532
Tumor size (cm)	5.52 ± 1.95	5.20 ± 1.88	0.428
Tumor number, n (%)			0.948
1	24 (64.86)	38 (65.52)
≥ 2	13 (35.14)	20 (34.48)
Tumor location, n (%)			0.637
Right lobe	17 (45.95)	23 (39.66)
Left lobe	14 (37.84)	21 (36.21)
Bilateral lobes	6 (16.22)	14 (24.14)
Liver cirrhosis (yes/no), n (%)	31/6	51/7	0.566
HBV infection (yes/no), n (%)	29/8	44/14	0.777
AFP, n (%)			0.532
< 400 (ng/mL)	28 (75.68)	47 (81.03)
≥ 400 (ng/mL)	9 (24.32)	11 (18.97)
Liver function, n (%)			1.000
Child-Pugh A	34 (91.89)	54 (93.10)
Child-Pugh B	3 (8.11)	4 (6.90)
Preoperative lab examination
ALB (g/L)	41.38 ± 5.75	40.89 ± 5.30	0.675
TBIL (μmol/L)	12.75 ± 3.57	13.88 ± 4.87	0.198
PT (s)	12.39 ± 1.27	12.18 ± 1.19	0.424
ALT (U/L)	27.87 ± 9.69	29.58 ± 12.12	0.469
AST (U/L)	30.56 ± 10.25	33.42 ± 11.72	0.229

BMI: Body mass index; HBV: Hepatitis B virus; AFP: Alpha fetoprotein; ALB: Albumin; TBIL: Total bilirubin; PT: Prothrombin time; ALT: Alanine aminotransferas; AST: Aspartate aminotransferase.